menu
    • menu
    [{"orgOrder":0,"company":"Signet","sponsor":"Juno Pharmaceuticals Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Signet \/ Signet Healthcare Partners","highestDevelopmentStatusID":"12","companyTruncated":"Signet \/ Signet Healthcare Partners"},{"orgOrder":0,"company":"Signet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"sigx1094","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Signet \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Signet \/ Not Applicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SIGX1094","moa":"FAK\/YAP","graph1":"Oncology","graph2":"Phase I","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Signet \/ Inapplicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SIGX1094","moa":"FAK","graph1":"Oncology","graph2":"Phase I","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Signet \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Signet

    Menu

    Signet

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Signet

                            India arrow
                            The Generic Rx Session
                            Not Confirmed

                            Signet

                            India arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIGX1094

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track to World’s First Therapy for Diffuse Gastric Cancer

                            Details : SIGX1094, an investigational small molecule and the first targeted drug candidate for diffuse gastric cancer, has received fast track designation from the FDA.

                            Product Name : SIGX1094

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : SIGX1094

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Signet

                            India arrow
                            The Generic Rx Session
                            Not Confirmed

                            Signet

                            India arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIGX1094

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Organoid-AI Drug Candidate Doses First Patient in Diffuse Gastric Cancer

                            Details : Sigx1094 targets FAK and YAP, which are crucial for cancer cell survival and proliferation, sigx1094 aims to disrupt the cellular mechanisms that enable tumor growth and metastasis.

                            Product Name : SIGX1094

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 14, 2025

                            Lead Product(s) : SIGX1094

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Signet

                            India arrow
                            The Generic Rx Session
                            Not Confirmed

                            Signet

                            India arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : sigx1094

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Signet Therapeutics Receives IND Approval for Targeted Therapy for Diffuse Gastric Cancer

                            Details : Sigx1094, an investigational small molecule and the first targeted drug candidate for diffuse gastric cancer, has received IND approval from the FDA.

                            Product Name : sigx1094

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 01, 2024

                            Lead Product(s) : sigx1094

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Signet

                            India arrow
                            The Generic Rx Session
                            Not Confirmed

                            Signet

                            India arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Juno Pharmaceuticals Pty Ltd

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Signet Healthcare Partners Completes Growth Equity Investment in Juno Pharmaceuticals Corp.

                            Details : Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and sp...

                            Product Name : Adrenaline Aguettant-Generic

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 24, 2022

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Juno Pharmaceuticals Pty Ltd

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth